Palermo M, Shackleton C H, Mantero F, Stewart P M
Children's Hospital Oakland Research Institute, CA 94609, USA.
Clin Endocrinol (Oxf). 1996 Nov;45(5):605-11. doi: 10.1046/j.1365-2265.1996.00853.x.
Two isoforms of 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD) catalyse the interconversion of cortisol to hormonally inactive cortisone; defects in the 11 beta-HSD2 isoform result in hypertension. The kidney, expressing high levels of 11 beta-HSD2, is the principal source of cortisone in man. We have validated the measurement of urinary free cortisone (UFE) excretion in normals and in patients with disorders of the pitultary-adrenal axis in an attempt to more accurately measure the activity of 11 beta-HSD2 in vivo.
Forty-one normal adults, 12 normal children < 12 years of age, 15 patients with Cushing's syndrome, 12 with hypopitultarism on replacement hydrocortisone, 12 with the syndrome of apparent mineralocorticoid excess (AME) and 7 volunteers consuming liquorice.
A complete 24-hour urine collection was analysed by gas chromatography/mass spectrometry for "A-ring' reduced cortisol and cortisone metabolites, i.e. tetrahydrocortisols (THF and allo-THF) and tetrahydrocortisone (THE). In addition, urinary free cortisol (UFF) and urinary free cortisone were quantified using deuterium-labelled internal standards.
In normal adults and children, UFE excretion exceeded that of UFF (UFF 30.4 +/- 2.4 micrograms/24h (mean +/- SE), UFE 54.6 +/- 4.1 micrograms/24h, adults) (for conversion to nmol/24h multiply E by 2.78 and F by 2.76 respectively). Thus the normal UFF/UFE ratio was 0.54 +/- 0.05 in contrast to the (THF + allo-THF)/THE ratio of 1.21 +/- 0.06. UFE excretion was normal in hypopituitary patients on replacement hydrocortisone. Although UFE was elevated in all forms of Cushing's syndrome, the UFF/UFE ratio was grossly elevated in patients with the ectopic ACTH syndrome (14.0 +/- 6.7, n = 6). UFE was below the lower limit of the assay (< 1 microgram/24h) in most patients with the so-called type 1 variant of AME and significantly reduced in 4 patients described as having the type 2 variant of AME (10.5 +/- 3.5 micrograms/h, P < 0.05) and in 7 volunteers consuming liquorice (26.8 +/- 10.0 micrograms/24h, P < 0.01). In ectopic ACTH syndrome, AME, and liquorice ingestion the UFF/UFE ratio was more deranged than the (THF + allo-THF)/THE ratio.
In normals the discrepant THF + allo-THF/ THE and UFF/UFE ratio suggests that much more of the UFE is derived from the kidney. Reduction in UFE excretion is seen following liquorice ingestion and in both variants of AME, though it is more profound in AME1. The high UFF/UFE ratio in the mineralocorticoid excess state seen in the ectopic ACTH syndrome is compatible with substrate-saturation of renal 11 beta-HSD2. The measurement of UFE and the UFF/UFE ratio is a significant advance in the analysis of human 11 beta-HSD activity in vivo; in particular, the UFF/UFE ratio appears to be a more sensitive index than the (THF + allo-THF)/THE ratio of renal 11 beta-HSD2 activity.
11β-羟类固醇脱氢酶(11β-HSD)的两种同工型催化皮质醇与激素无活性的可的松之间的相互转化;11β-HSD2同工型缺陷会导致高血压。肾脏中11β-HSD2表达水平较高,是人体可的松的主要来源。我们已验证了正常人和垂体-肾上腺轴紊乱患者尿游离可的松(UFE)排泄量的测定方法,旨在更准确地测定体内11β-HSD2的活性。
41名正常成年人、12名12岁以下的正常儿童、15名库欣综合征患者、12名接受氢化可的松替代治疗的垂体功能减退患者、12名表观盐皮质激素过多综合征(AME)患者以及7名食用甘草的志愿者。
通过气相色谱/质谱法分析24小时完整尿液收集样本中的“A环”还原型皮质醇和可的松代谢产物,即四氢皮质醇(THF和别-THF)和四氢可的松(THE)。此外,使用氘标记内标对尿游离皮质醇(UFF)和尿游离可的松进行定量。
在正常成年人和儿童中,UFE排泄量超过UFF(成年人中,UFF为30.4±2.4微克/24小时(均值±标准误),UFE为54.6±4.1微克/24小时)(如需换算为纳摩尔/24小时,分别将E乘以2.78,F乘以2.76)。因此,正常情况下UFF/UFE比值为0.54±0.05,而(THF+别-THF)/THE比值为1.21±0.06。接受氢化可的松替代治疗的垂体功能减退患者UFE排泄量正常。虽然所有形式的库欣综合征患者UFE均升高,但异位促肾上腺皮质激素(ACTH)综合征患者的UFF/UFE比值显著升高(14.0±6.7,n=6)。大多数所谓1型AME变异患者的UFE低于检测下限(<1微克/24小时),4名被描述为2型AME变异的患者以及7名食用甘草的志愿者的UFE显著降低(分别为10.5±3.5微克/小时,P<0.05和26.8±10.0微克/24小时,P<0.01)。在异位ACTH综合征、AME和食用甘草的情况下,UFF/UFE比值比(THF+别-THF)/THE比值紊乱更严重。
在正常人中,THF+别-THF/THE与UFF/UFE比值不一致,提示更多的UFE来源于肾脏。食用甘草后以及两种AME变异患者中均可见UFE排泄量降低,不过在AME1中更为明显。异位ACTH综合征中盐皮质激素过多状态下较高的UFF/UFE比值与肾脏11β-HSD2的底物饱和相符。UFE和UFF/UFE比值的测定是体内人类11β-HSD活性分析的一项重大进展;特别是,UFF/UFE比值似乎是比(THF+别-THF)/THE比值更敏感的肾脏11β-HSD2活性指标。